 | • レポートコード：MRC2302F0232 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、234ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年の2,246.72百万ドルであった世界の痛風治療薬市場規模が、2022年に2,486.64百万ドルへ達し、2027年までに年平均10.85%成長し、4,169.63百万ドルへ拡大すると見込んでいます。本書は、痛風治療薬の世界市場を対象に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬物クラス別（コルヒチン、副腎皮質ステロイド、非ステロイド性抗炎症薬、尿酸降下薬）分析、治療薬別（尿毒症治療薬、キサンチンオキシダーゼ阻害剤）分析、投与経路別（経口、非経口）分析、用途別（急性痛風、慢性痛風）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目について調査・分析を行っています。また、市場調査の対象企業には、Alder Biopharmaceuticals、Antares Pharma、Astellas Pharma、Boehringer Ingelheim、Can-Fite Biopharma、Eli Lilly、GlaxoSmithKline、Ironwood Pharmaceuticals、JW Pharmaceutical、KaloBios Pharmaceuticalsなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の痛風治療薬市場規模：薬物クラス別 - コルヒチンの市場規模 - 副腎皮質ステロイドの市場規模 - 非ステロイド性抗炎症薬の市場規模 - 尿酸降下薬の市場規模 ・世界の痛風治療薬市場規模：治療薬別 - 尿毒症治療薬における市場規模 - キサンチンオキシダーゼ阻害剤における市場規模 ・世界の痛風治療薬市場規模：投与経路別 - 経口における市場規模 - 非経口における市場規模 ・世界の痛風治療薬市場規模：用途別 - 急性痛風における市場規模 - 慢性痛風における市場規模 ・世界の痛風治療薬市場規模：地域別 - 南北アメリカの痛風治療薬市場規模 アメリカの痛風治療薬市場規模 カナダの痛風治療薬市場規模 ブラジルの痛風治療薬市場規模 ... - アジア太平洋の痛風治療薬市場規模 日本の痛風治療薬市場規模 中国の痛風治療薬市場規模 インドの痛風治療薬市場規模 韓国の痛風治療薬市場規模 台湾の痛風治療薬市場規模 ... - ヨーロッパ/中東/アフリカの痛風治療薬市場規模 イギリスの痛風治療薬市場規模 ドイツの痛風治療薬市場規模 フランスの痛風治療薬市場規模 ロシアの痛風治療薬市場規模 ... - その他地域の痛風治療薬市場規模 ・競争状況 ・企業情報 |
The Global Gout Therapeutics Market size was estimated at USD 2,246.72 million in 2021 and expected to reach USD 2,486.64 million in 2022, and is projected to grow at a CAGR 10.85% to reach USD 4,169.63 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Gout Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the market was studied across Colchicine, Corticosteroids, NSAIDs, and Urate-lowering Agents.
Based on Treatment, the market was studied across Uricosuria Medication and Xanthine Oxidase Inhibitor.
Based on Route of Administration, the market was studied across Oral and Parenteral.
Based on Application, the market was studied across Acute Gout and Chronic Gout.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Gout Therapeutics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Gout Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Gout Therapeutics Market, including Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, Boehringer Ingelheim, Can-Fite Biopharma, Eli Lilly, GlaxoSmithKline, Ironwood Pharmaceuticals, JW Pharmaceutical, and KaloBios Pharmaceuticals.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Gout Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Gout Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Gout Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Gout Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Gout Therapeutics Market?
6. What is the market share of the leading vendors in the Global Gout Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Gout Therapeutics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of Gout with increasing alcohol consumption
5.1.1.2. Growing geriatric population
5.1.1.3. Introduction to urate-lowering agents segment
5.1.2. Restraints
5.1.2.1. Competition from generic drugs and high cost of drugs
5.1.3. Opportunities
5.1.3.1. Technological advancements in imaging modalities improved understanding of gout
5.1.3.2. Increasing R&D activities on regenerative medicines
5.1.4. Challenges
5.1.4.1. Side Effects of Gout Therapeutic Drugs
5.2. Cumulative Impact of COVID-19
6. Gout Therapeutics Market, by Drug Class
6.1. Introduction
6.2. Colchicine
6.3. Corticosteroids
6.4. NSAIDs
6.5. Urate-lowering Agents
7. Gout Therapeutics Market, by Treatment
7.1. Introduction
7.2. Uricosuria Medication
7.3. Xanthine Oxidase Inhibitor
8. Gout Therapeutics Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Gout Therapeutics Market, by Application
9.1. Introduction
9.2. Acute Gout
9.3. Chronic Gout
10. Americas Gout Therapeutics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Gout Therapeutics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Gout Therapeutics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Alder Biopharmaceuticals
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Antares Pharma
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Astellas Pharma
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Boehringer Ingelheim
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Can-Fite Biopharma
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Eli Lilly
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. GlaxoSmithKline
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Ironwood Pharmaceuticals
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. JW Pharmaceutical
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. KaloBios Pharmaceuticals
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing